155 related articles for article (PubMed ID: 9451419)
1. WR-1065, an active metabolite of the cytoprotector amifostine, affects phosphorylation of topoisomerase II alpha leading to changes in enzyme activity and cell cycle progression in CHO AA8 cells.
Murley JS; Constantinou A; Kamath NS; Grdina DJ
Cell Prolif; 1997; 30(6-7):283-94. PubMed ID: 9451419
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of topoisomerase II alpha activity in CHO K1 cells by 2-[(aminopropyl)amino]ethanethiol (WR-1065).
Grdina DJ; Constantinou A; Shigematsu N; Murley JS
Radiat Res; 1994 Apr; 138(1):44-52. PubMed ID: 8146299
[TBL] [Abstract][Full Text] [Related]
3. Effects of thiols on topoisomerase-II alpha activity and cell cycle progression.
Grdina DJ; Murley JS; Roberts JC
Cell Prolif; 1998; 31(5-6):217-29. PubMed ID: 9925989
[TBL] [Abstract][Full Text] [Related]
4. Further evidence that the radioprotective aminothiol, WR-1065, catalytically inactivates mammalian topoisomerase II.
Snyder RD; Grdina DJ
Cancer Res; 2000 Mar; 60(5):1186-8. PubMed ID: 10728671
[TBL] [Abstract][Full Text] [Related]
5. Drastic reduction of topoisomerase II alpha associated with major acquired resistance to topoisomerase II active agents but minor perturbations of cell growth.
Hashimoto S; Chatterjee S; Ranjit GB; Bao C; Ford J; Ganapathi R; Berger SJ; Berger NA
Oncol Res; 1995; 7(7-8):407-16. PubMed ID: 8747604
[TBL] [Abstract][Full Text] [Related]
6. Interaction of amifostine and ionizing radiation on transcriptional patterns of apoptotic genes expressed in human microvascular endothelial cells (HMEC).
Khodarev NN; Kataoka Y; Murley JS; Weichselbaum RR; Grdina DJ
Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):553-63. PubMed ID: 15380592
[TBL] [Abstract][Full Text] [Related]
7. A unique paclitaxel-mediated modulation of the catalytic activity of topoisomerase IIalpha.
Dhawan V; Swaffar DS
Anticancer Drugs; 1999 Apr; 10(4):397-404. PubMed ID: 10378675
[TBL] [Abstract][Full Text] [Related]
8. Activation of the nuclear transcription factor kappaB (NFkappaB) and differential gene expression in U87 glioma cells after exposure to the cytoprotector amifostine.
Kataoka Y; Murley JS; Khodarev NN; Weichselbaum RR; Grdina DJ
Int J Radiat Oncol Biol Phys; 2002 May; 53(1):180-9. PubMed ID: 12007958
[TBL] [Abstract][Full Text] [Related]
9. Accumulation of CHO cells in G2 phase following exposure to WR-1065.
Murley JS; Grdina DJ; Meechan PJ
Radiat Res; 1991 May; 126(2):223-8. PubMed ID: 2023993
[TBL] [Abstract][Full Text] [Related]
10. Effects of growth media on cell cycle progression in CHO cells exposed to the radioprotector WR-1065.
Murley JS; Grdina DJ; Meechan PJ
Cell Prolif; 1992 Nov; 25(6):643-50. PubMed ID: 1457610
[TBL] [Abstract][Full Text] [Related]
11. The effects of cycloheximide and WR-1065 on radiation-induced repair processes: a mechanism for chemoprevention.
Murley JS; Grdina DJ
Carcinogenesis; 1995 Nov; 16(11):2699-705. PubMed ID: 7586189
[TBL] [Abstract][Full Text] [Related]
12. Chemical protection and cell-cycle effects on radiation-induced mutagenesis.
Grdina DJ; Sigdestad CP
Cell Prolif; 1992 Jan; 25(1):23-9. PubMed ID: 1540681
[TBL] [Abstract][Full Text] [Related]
13. Carbamate analogues of amsacrine active against non-cycling cells: relative activity against topoisomerases IIalpha and beta.
Turnbull RM; Meczes EL; Perenna Rogers M; Lock RB; Sullivan DM; Finlay GJ; Baguley BC; Austin CA
Cancer Chemother Pharmacol; 1999; 44(4):275-82. PubMed ID: 10447574
[TBL] [Abstract][Full Text] [Related]
14. Relationships between cytoprotection and mutation prevention by WR-1065.
Grdina DJ; Murley JS; Kataoka Y; Epperly W
Mil Med; 2002 Feb; 167(2 Suppl):51-3. PubMed ID: 11873516
[TBL] [Abstract][Full Text] [Related]
15. Attenuation of drug-stimulated topoisomerase II-DNA cleavable complex formation in wild-type HL-60 cells treated with an intracellular calcium buffer is correlated with decreased cytotoxicity and site-specific hypophosphorylation of topoisomerase IIalpha.
Aoyama M; Grabowski DR; Dubyak GR; Constantinou AI; Rybicki LA; Bukowski RM; Ganapathi MK; Hickson ID; Ganapathi R
Biochem J; 1998 Dec; 336 ( Pt 3)(Pt 3):727-33. PubMed ID: 9841887
[TBL] [Abstract][Full Text] [Related]
16. Phosphorylation-independent stimulation of DNA topoisomerase II alpha activity.
Kimura K; Saijo M; Tanaka M; Enomoto T
J Biol Chem; 1996 May; 271(18):10990-5. PubMed ID: 8631919
[TBL] [Abstract][Full Text] [Related]
17. Topoisomerase II is nonfunctional in polyamine-depleted cells.
Alm K; Berntsson P; Oredsson SM
J Cell Biochem; 1999 Oct; 75(1):46-55. PubMed ID: 10462703
[TBL] [Abstract][Full Text] [Related]
18. Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines.
Sehested M; Wessel I; Jensen LH; Holm B; Oliveri RS; Kenwrick S; Creighton AM; Nitiss JL; Jensen PB
Cancer Res; 1998 Apr; 58(7):1460-8. PubMed ID: 9537249
[TBL] [Abstract][Full Text] [Related]
19. Cell-cycle-dependent phosphorylation and activity of Chinese-hamster ovary topoisomerase II.
Burden DA; Goldsmith LJ; Sullivan DM
Biochem J; 1993 Jul; 293 ( Pt 1)(Pt 1):297-304. PubMed ID: 8392338
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical and two-parameter flow cytometric studies of DNA topoisomerase II alpha in human epithelial ovarian carcinoma and germ cell tumor.
Tanoguchi K; Sasano H; Yabuki N; Kikuchi A; Ito K; Sato S; Yajima A
Mod Pathol; 1998 Feb; 11(2):186-93. PubMed ID: 9504690
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
